J&J presses on with drug to prevent premature ejaculation

07/10/2007 | Wall Street Journal (free content), The

Other drugmakers have abandoned their search for a drug to prevent premature ejaculation, but Johnson & Johnson, whose first try was rejected by the FDA, is still in the hunt. The company intends to test its dapoxetine outside the U.S. and file for regulatory approval in Europe and Canada later this year. The FDA declined to approve it in 2005, questioning its medical benefit.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD